Sevofluorane

Phase 3Small molecule

TTamas Vegh, MD

Sevofluorane is one of 3 small molecule programs targeting Craniosynostosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CraniosynostosisEnrolling by invitation

CraniosynostosisPhase 3

Enrolling by invitation

Competition

Competitive Landscape

3 competitors in Craniosynostosis

#DrugCompanyPhaseTrials

Sevofluorane

TTamas Vegh, MD

Phase 3

1 2

Cyklokapron

JJ Molner

Preclinical

1 3

Ferrous Fumarate or Ferrostrane

UUniversity Hospital, Montpellier

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Agitation1 trial

The Effect of Induction Technique on Postoperative Pain and Agitation

Completed·MMustafa Kemal University·Phase 4·NCT02110745·2 enrolled

Craniosynostosis1 trial

Measuring of the Duration of Action of Different Doses of Rocuronium-induced Neuromuscular Block in Infants During Surgical Treatment of Craniosynostosis

Enrolling by invitation·TTamas Vegh, MD·Phase 4·NCT07080528·20 enrolled

Mitral Valve Surgery1 trial

Preconditioning With Sevoflurane and Propofol in Patients Undergoing Minimally Invasive Mitral Valve Surgery

Unknown status·FFondazione Toscana Gabriele Monasterio··NCT02551328·48 enrolled

Intracranial Pressure1 trial

Volatile Versus Total Intravenous Anesthesia and Optic Nerve Sheath Diameter During Laparoscopic Cholecystectomy: A Randomized Controlled Trial

Completed·BBagcilar Training and Research Hospital·Approved·NCT07786740·80 enrolled

Postoperative Recovery1 trial

Effect of Combined Intravenous-Inhalational Anesthesia (CIVIA) on Postoperative Recovery Patterns.

Completed·KKocaeli City Hospital·Approved·NCT07123870·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sevofluorane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sevofluorane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sevofluorane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tamas Vegh, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTamas Vegh, MD

Sevofluorane

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Agitation1 trial

Craniosynostosis1 trial

Mitral Valve Surgery1 trial

Intracranial Pressure1 trial

Postoperative Recovery1 trial

References

Drug Info

Quick Facts

Related News